Canagliflozin Linked to Improved Anemia in Patients with Diabetes and Renal Disease
Mar 27, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Adrian Gavre, PharmD Candidate, Philadelphia College of Osteopathic Medicine
SGLT-2 inhibitors show additional benefits besides lowering blood glucose.
SGLT-2 inhibitors such as canagliflozin are shown to be beneficial to patients who have both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in regards to developing anemia. Canagliflozin targets sodium-glucose cotransporter 2 within renal cells, resulting in increased excretion of glucose through the urine and decreasing glucose reabsorption rates of filtered glucose.
According to a recent post-hoc analysis of the CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation), there was a statistically significant difference in the risk of developing anemia and other anemia events between the placebo and canagliflozin group....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.